Claims
- 1. A carbostyril compound represented by the formula (I): ##STR38## and the ring A has a partial structure: ##STR39## wherein R.sup.1, R.sup.2 and R.sup.3, which may be the same or different, each represents a hydrogen atom, a cycloalkylcarbonyl group having 4 to 8 carbon atoms, a cycloalkylalkanoyl group having 3 to 7 carbon atoms in the cycloalkyl moiety and 2 to 4 carbon atoms in the alkanoyl moiety, a benzoyl group, an alkanoyl group having 2 to 6 carbon atoms or a phenylalkylcarbonyl group having 1 to 4 carbon atoms in the alkyl moiety; R.sup.4 represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms, R.sup.5 and R.sup.6, which may be the same or different, each represents a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, a cycloalkyl group having 4 to 6 carbon atoms, or a phenylalkyl group having 1 to 4 carbon atoms in the alkyl moiety, or R.sup.5 and R.sup.6 may, when taken together with the nitrogen atom to which they are attached, form a heterocyclic ring selected from the group consisting of pyrrolidino, piperidino, morpholino and piperazino, which heterocyclic ring can be unsubstituted or substituted with an alkyl group having 1 to 4 carbon atoms; with the proviso that at least one of R.sup.1, R.sup.2 and R.sup.3 represents said cycloalkylcarbonyl group, said cycloalkylalkanoyl group, said benzoyl group, said alkanoyl group, or said phenylalkylcarbonyl group and each of R.sup.1 and R.sup.2 is not a hydrogen atom when R.sup.3 is absent; and pharmaceutically acceptable acid addition salts of said carbostyril compounds of the formula (I).
- 2. The carbostyril compound according to claim 1 represented by the formula (Ib): ##STR40## wherein R.sup.1, R.sup.2, R.sup.4, R.sup.5 and R.sup.6 are as defined in claim 1, and the pharmaceutically acceptable acid addition salts thereof.
- 3. 5-(1-Isobutyryloxy-2-isopropylaminobutyl)-8-isobutyryloxycarbostyril, according to claim 2.
- 4. 8-Acetoxy-5-(1-acetoxy-2-isopropylaminobutyl)carbostyril, according to claim 2.
- 5. 5-(1-Cyclohexylcarbonyloxy-2-isopropylaminobutyl)-8-cyclohexylcarbonyloxycarbostyril, according to claim 2.
- 6. 5-(1-p-Methylbenzoyloxy-2-isopropylaminobutyl)-8-p-methylbenzoyloxycarbostyril, according to claim 2.
- 7.5-(1-p-Methylbenzoyloxy-2-isopropylaminobutyl)-8-p-methylbenzoyloxy-3,4-dihydrocarbostyril, according to claim 2.
- 8. 8-Cyclohexylcarbonyloxy-5-(1-isobutyryloxy-2-isopropylaminobutyl)carbostyril, according to claim 2.
- 9. 8-Toluyloxy-5-(1-cyclohexylcarbonyloxy-2-isopropylaminobutyl)carbostyril, according to claim 2.
- 10. 5-[1-Cyclopropylcarbonyloxy-2-(3,4-dimethoxyphenethylamino)ethyl]-8-cyclopropylcarbonyloxycarbostyril, according to claim 2.
- 11. The carbostyril compound according to claim 1 represented by the formula (Ia): ##STR41## wherein R.sup.1 represents said cycloalkylcarbonyl group, said cycloakylalkanoyl group, said benzoyl group, said alkanoyl group or said phenylalkylcarbonyl group and R.sup.4, R.sup.5 and R.sup.6 are as defined in claim 1, and the pharmaceutically acceptable acid addition salts thereof.
- 12. 5-(1-Hydroxy-2-isopropylaminobutyl)-8-isobutyryloxycarbostyril, according to claim 11.
- 13. 5-(1-Hydroxy-2-ethylaminobutyl)-8-acetoxycarbostyril, according to claim 11.
- 14. 5-(1-Hydroxy-2-tert-butylaminopropyl)-8-isobutyryloxy carbostyril, according to claim 11.
- 15. 5-(1-Hydroxy-2-isopropylaminobutyl)-8-isobutyryloxy-3,4-dihydrocarbosytril, according to claim 11.
- 16. 5-(1-Hydroxy-2-isopropylaminobutyl)-8-cyclohexylcarbonyloxycarbostyril, according to claim 11.
- 17. 5-(1-Hydroxy-2-isopropylaminobutyl)-8-p-methylbenzoyloxycarbostyril, according to claim 11.
- 18. 5-(1-Hydroxy-2-isopropylaminobutyl)-8-p-methylbenzoyloxy-3,4-dihydrocarbostyril, according to claim 11.
- 19. 5-(1-Hydroxy-2-.alpha.,.alpha.-dimethylphenethylaminoethyl)-8-cyclohexylcarbonyloxycarbostyril, according to claim 11.
- 20. 5-(1-Hydroxy-2-isopropylaminobutyl)-8-(3,4-dimethoxyphenylcarbonyloxy)carbostyril, according to claim 11.
- 21. 5-(1-Hydroxy-2-ethylaminobutyl)-8-(.beta.-cyclohexylpropionyloxy)carbostyril, according to claim 11.
- 22. 5-(1-Hydroxy-2-isopropylaminobutyl)-8-phenylacetyloxycarbostyril, according to claim 11.
- 23. 5-(1-Hydroxy-2-benzylaminobutyl)-8-(p-chlorobenzoyloxy)carbostyril, according to claim 11.
- 24. 5-(1-Hydroxy-2-tert-butylaminopropyl)-8-(3,4-methylenedioxyphenylcarbonyloxy)carbostyril, according to claim 11.
- 25. 5-(1-Hydroxy-2-isopropylaminobutyl)-8-(3,3-dimethylbutyryloxy)carbostyril, according to claim 11.
- 26. The carbostyril compound according to claim 1 represented by the formula (Id) ##STR42## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are as defined in claim 1, and the pharmaceutically acceptable acid addition salts thereof.
- 27. The carbostyril compound of claim 1 wherein each of R.sup.1 and R.sup.2, which may be the same or different, do not represent a hydrogen atom.
- 28. The carbostyril compound according to claim 2 wherein each of R.sup.1 and R.sup.2, which may be the same or different, do not represent a hydrogen atom.
- 29. The carbostyril compound according to claim 26 wherein R.sup.1, R.sup.2 and R.sup.3 which may be the same or different, each do not represent a hydrogen atom.
- 30. The carbostyril compound according to claim 1 wherein the carbon-to-carbon bonding between the 3 and 4 position of the carbostyril nucleus is a double bond, and the pharmaceutically acceptable acid addition salts thereof.
- 31. The carbostyril compound according to claim 26 wherein R.sup.4 represents an alkyl group, and the pharmaceutically acceptable acid addition salts thereof.
- 32. The carbostyril compound according to claim 1 wherein R.sup.4 represents a hydrogen atom, and the pharmaceutically acceptable acid addition salts thereof.
- 33. The carbostyril compound according to claim 1 wherein R.sup.1 represents a benzoyl group, and the pharmaceutically acceptable acid addition salts thereof.
- 34. The carbostyril compound according to claim 1 wherein R.sup.1 represents an alkanoyl group, and the pharmaceutically acceptable acid addition salts thereof.
- 35. The carbostyril compound according to claim 1 wherein R.sup.1 represents a phenylalkylcarbonyl group, and the acid addition salts thereof.
- 36. The carbostyril compound according to claim 1 wherein R.sup.1 represents a cycloalkylcarbonyl group, and the pharmaceutically acceptable acid addition salts thereof.
- 37. The carbostyril compound to claim 1 wherein R.sup.1 represents a cycloalkylalkanoyl group, and the pharmaceutically acceptable acid addition salts thereof.
- 38. 8-(4-methylbenzoyloxy)-5-(1-hydroxy-2-ethylaminobutyl)-carbostyril, according to claim 1.
Priority Claims (1)
Number |
Date |
Country |
Kind |
51/121423 |
Oct 1976 |
JPX |
|
Parent Case Info
This is a continuation of Ser. No. 756,651, filed Jan. 4, 1977, now abandoned.
US Referenced Citations (6)
Number |
Name |
Date |
Kind |
3975391 |
Nakagawa et al. |
Aug 1976 |
|
3994901 |
Nakagawa et al. |
Nov 1976 |
|
4022776 |
Nakagawa et al. |
May 1977 |
|
4022784 |
Nakagawa et al. |
May 1977 |
|
4026897 |
Nakagawa et al. |
May 1977 |
|
4072683 |
Nakagawa et al. |
Feb 1978 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
823841 |
Jan 1975 |
BEX |
Continuations (1)
|
Number |
Date |
Country |
Parent |
756651 |
Jan 1977 |
|